Cargando…

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab

BACKGROUND: Hepcidin, the systemic iron regulator, could be critical in differentiating iron deficiency (ID) from functional iron restriction in inflammatory bowel disease (IBD). We assessed hepcidin as a diagnostic ID marker and explored the relationship between hepcidin and its regulators in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loveikyte, Roberta, Bourgonje, Arno R, van der Reijden, Johannes J, Bulthuis, Marian L C, Hawinkels, Lukas J A C, Visschedijk, Marijn C, Festen, Eleonora A M, van Dullemen, Hendrik M, Weersma, Rinse K, van Goor, Harry, van der Meulen-de Jong, Andrea E, Dijkstra, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393210/ https://www.ncbi.nlm.nih.gov/pubmed/36748574 http://dx.doi.org/10.1093/ibd/izad010

Ejemplares similares

Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn’s Disease
por: Alexdottir, Marta S., et al.
Publicado: (2022)

Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
por: Alexdottir, Marta S., et al.
Publicado: (2022)

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease
por: Otten, Antonius T., et al.
Publicado: (2022)

Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease
por: Karmi, Naomi, et al.
Publicado: (2021)

Environmental factors associated with biological use and surgery in inflammatory bowel disease
por: van der Sloot, Kimberley W J, et al.
Publicado: (2020)

The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum
por: Loveikyte, R., et al.
Publicado: (2023)

Long-Term Dietary Patterns Are Reflected in the Plasma Inflammatory Proteome of Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease
por: van der Sloot, Kimberley W J, et al.
Publicado: (2020)

Riboflavin Supplementation in Patients with Crohn’s Disease [the RISE-UP study]
por: von Martels, Julius Z H, et al.
Publicado: (2020)

A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease
por: Gabriëls, Ruben Y., et al.
Publicado: (2022)

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD
por: Otten, Antonius T, et al.
Publicado: (2023)

The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R, et al.
Publicado: (2021)

Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options
por: Bourgonje, Arno R., et al.
Publicado: (2021)

Crohn’s Disease in Clinical Remission Is Marked by Systemic Oxidative Stress
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
por: Zou, Fangwen, et al.
Publicado: (2021)

The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
por: Imhann, Floris, et al.
Publicado: (2019)

Oxidative Stress Predicts Post-Surgery Complications in Gastrointestinal Cancer Patients
por: Leimkühler, M., et al.
Publicado: (2022)

Acute serum free thiols: a potentially modifiable biomarker of oxidative stress following traumatic brain injury
por: Visser, Koen, et al.
Publicado: (2022)

Correction to: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
por: Imhann, Floris, et al.
Publicado: (2019)

Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
por: Bourgonje, Arno R., et al.
Publicado: (2023)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD
por: Hu, Shixian, et al.
Publicado: (2021)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection
por: Frost, Joe N., et al.
Publicado: (2021)

Large-scale genetic analyses in an understudied disease: haemorrhoidal disease
por: Festen, Eleonora A M, et al.
Publicado: (2021)

Acute Kidney Injury is Associated with Lowered Plasma-Free Thiol Levels
por: Boekhoud, Lisanne, et al.
Publicado: (2020)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ)
por: van der Sloot, Kimberley Wilhelmina Johanna, et al.
Publicado: (2018)

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2
por: Visschedijk, Marijn C., et al.
Publicado: (2016)

Local and Systemic Oxidative Stress Biomarkers for Male Infertility: The ORION Study
por: Bergsma, Anna T., et al.
Publicado: (2022)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022)

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Infliximab/vedolizumab: Drug-induced lupus, pneumonitis and lack of efficacy: case report
Publicado: (2021)

Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion
por: Kramer, Sjoerd, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6g7io69ufdgpv90na31cfaptn8